Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8292131 | 0.81 | SLC9A1 (0.57) | — | |
| SCHEMBL5087619 | 0.80 | SLC9A1 (0.48) | KDM4EHSD17B10VCAM1PTGS2SMN1; SMN2 | |
| SCHEMBL5090694 | 0.79 | NR1I2 (0.40) | KDM4EALDH1A1HPGDHSD17B10VCAM1 | |
| SCHEMBL5089733 | 0.78 | AKR1C3 (0.42) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL2947868 | 0.78 | KCNQ3 (0.42) | KDM4EHPGDHSD17B10VCAM1SMN1; SMN2 | |
| SCHEMBL4277107 | 0.75 | SLC9A1 (0.39) | KDM4EMAPTHSD17B10VCAM1SMN1; SMN2 | |
| SCHEMBL6749760 | 0.72 | SLC9A1 (0.54) | KDM4EALDH1A1MAPTHSD17B10VCAM1 | |
| SCHEMBL8925017 | 0.72 | KDM4E (0.39) | KDM4EALDH1A1MAPTHPGDPTGS1 | |
| SCHEMBL8580625 | 0.71 | SLC9A1 (0.45) | KDM4EALDH1A1MAPTHSD17B10VCAM1 | |
| SCHEMBL5089742 | 0.71 | AKR1C3 (0.48) | KDM4EMAPTHSD17B10ALOX15VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658266-B1 | PENTAFLUOROSULFANYL PHENYL-SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AGENTS AND MEDICAMENT CONTAINING SAID COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-11 | — | — | EP | disclosed |
| US-7381841-B2 | Cardiovascular disorders; antiischemic agenst | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-03 | — | — | US | disclosed |
| US-7381841-B2 | Cardiovascular disorders; antiischemic agenst | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-03 | — | — | US | disclosed |
| US-7381841-B2 | Cardiovascular disorders; antiischemic agenst | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-03 | — | — | US | disclosed |
| US-20050043401-A1 | Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043401-A1 | Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | TNNI3, TNNT2, RYR2 | KDM4E 3966/4885ALDH1A1 684/4885MAPT 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.